---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-306032"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2023-12-29T23:59:59+00:00"
generated_at: "2026-06-07T05:44:08.648671+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexicon enters $75M at-the-market equity offering agreement with Jefferies

## Summary
- Company may sell up to $75M of common stock through Jefferies in at-the-market offerings.
- Jefferies receives 3.0% commission on gross proceeds; company also reimburses legal fees.
- Invus affiliate (largest stockholder) has right to purchase shares to maintain ownership, subject to conditions.
- Proceeds intended to fund commercial launch of INPEFA (sotagliflozin), R&D, and working capital.
- Shares issued under existing shelf registration; prospectus supplement filed Dec 29, 2023.

## SEC filing metadata
- accession: 0001193125-23-306032
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2023-12-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000119312523306032/0001193125-23-306032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000119312523306032/d673597d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-306032
- JSON: https://secwatch.observer/filing/0001193125-23-306032.json
- Plain text: https://secwatch.observer/filing/0001193125-23-306032.txt

## Key facts
- Material Agreements
  LEXICON PHARMACEUTICALS, INC. entered into Open Market Sale Agreement with Jefferies LLC valued at up to $75,000,000 (effective 2023-12-29).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: up to $75,000,000
  - Effective: 2023-12-29
  source text: On December 29, 2023, Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”) entered into an Open Market Sale Agreement SM (the “ Agreement ”) with Jefferies LLC, as sales agent (“ Jefferies ”), pursuant to which the Company may offer and sell, from time to time, through Jefferies (the “public offerings”), shares of its common stock, par value $0.001, having an aggregate sales price of up to $75,000,000 (the “ Shares ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1062822/000119312523306032/0001193125-23-306032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.